Enforcement Report - Week of July 26, 2023
WASHINGTON, April 17 (Reuters) - The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals Corp's (NOVN.S) bid to revive a key patent on its blockbuster multiple sclerosis drug Gilenya that was invalidated amid a legal dispute with China's HEC Pharm Co Ltd (1558.HK).
Vyne Therapeutics is putting its mash-up of Pfizer’s Xeljanz and Novartis’ Gilenya on the back burner. After sifting through the data from a failed midphase eczema trial, the biotech has begun searching for a partner for the program to free up its own cash for development of its BET inhibitors.
BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (Cycle) has today announced the launch of TASCENSO ODT, its first product to treat MS patients in the US. The launch ensures MS patients in the US currently benefitting from Gilenya, or generic fingolimod, can access appropriate patient support services alongside the bioequivalent, non-generic, TASCENSO ODT. Gilenya patient support services are scheduled to be withdrawn on March 31st 2023.1,2,3
After fighting for months to protect its Gilenya patent and losing in federal appeals court, Novartis has taken its complaint to the Supreme Court.
Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT® (fingolimod)
After taking its Gilenya patent battle all the way to the Supreme Court last month, Novartis suffered yet another loss on Thursday — but it isn’t done fighting yet.
WASHINGTON, Oct 13 (Reuters) - The U.S. Supreme Court on Thursday turned down Novartis' (NOVN.S) bid to block the launch of generic versions of the company's blockbuster multiple sclerosis drug Gilenya in a dispute with China's HEC Pharm Co Ltd (1558.HK) and other generic drugmakers.
Bionpharma's Generic Fingolimod Hydrochloride Receives Approval in the U.S.
Novartis stands to lose more than a quarter billion dollars in sales this year if Gilenya generics are allowed to market. So it’s taking the fight all the way to the Supreme Court.